TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

LYRICA CR

PREGABALIN
Neurology Approved 2017-10-11
1
Indication
--
Phase 3 Trials
8
Years on Market

Details

Status
Prescription
First Approved
2017-10-11
Routes
ORAL
Dosage Forms
TABLET, EXTENDED RELEASE

Companies

Active Ingredient: PREGABALIN

LYRICA CR Approval History

Loading approval history...

What LYRICA CR Treats

3 indications

LYRICA CR is approved for 3 conditions since its original approval in 2017. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Neuropathic Pain
  • Diabetic Peripheral Neuropathy
  • Postherpetic Neuralgia
Source: FDA Label
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

LYRICA CR FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

LYRICA CR is indicated for the management of: • Neuropathic pain associated with diabetic peripheral neuropathy • Postherpetic neuralgia Efficacy of LYRICA CR has not been established for the management of fibromyalgia or as adjunctive therapy for adult patients with partial onset seizures. LYRICA CR is indicated for the management of: • Neuropathic pain associated with diabetic peripheral neuropathy (DPN) • Postherpetic neuralgia (PHN) Efficacy of LYRICA CR has not been established for the management of fibromyalgia or as adjunctive therapy for adult patients with partial onset seizures.

LYRICA CR Patents & Exclusivity

Latest Patent: May 2027

Patents (72 active)

US9144559*PED Expires May 2, 2027
US10022447*PED Expires May 2, 2027
US8945620*PED Expires May 2, 2027
US10022447 Expires Nov 2, 2026
US8945620 Expires Nov 2, 2026
US9144559 Expires Nov 2, 2026
+ 62 more patents
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.